Fig. 3

Plasma total cholesterol and HDL-cholesterol levels decreased after CS6253 treatment. A In the DRF study, decrease in plasma total cholesterol levels was significant at 2 h, 4 h, 12 h, 24 h, and 48 h p.i. (p = 0.002, p < 0.001, p < 0.001, p < 0.001, p = 0.001, respectively) and for accumulated treatment over time (p < 0.001). B In the GLP study, decrease in plasma total cholesterol levels was significant for treatment and for accumulated treatment over time (p < 0.001 for both), as well as at 12 h, 24 h, and 48 h p.i. (p < 0.001, p < 0.001, and p = 0.025, respectively). C In the DRF study, decrease in plasma HDL cholesterol levels was significant for 2 h, 4 h, 12 h, 24 h, and 48 h p.i. (p = 0.008, p < 0.001, p < 0.001, p < 0.001, p < 0.001, respectively) and for accumulated treatment over time (p < 0.001). D In the GLP study, decrease in plasma HDL cholesterol levels was significant for treatment and for accumulated treatment over time (p < 0.001 for both). Additionally, the time after injection was significantly correlated with HDL cholesterol levels in a quadratic model (p < 0.001). The values for the DRF study were shown as percent change from the baseline measurement while the values for the GLP study were shown as percent change from the first measurement point at 5 min p.i. on day 1. The analysis was done using a mixed-effects model, with cholesterol or HDL cholesterol levels modeled as a function of fixed effects including treatment (active compared with placebo), indicator variables for hours since injection (i.e., time of injection), and a linear variable for total time under study; a random intercept of subject was specified to model correlated outcomes arising from repeated measurements